On April 4, 2024, Ian Shakil, the Chief Strategy Officer of Augmedix Inc (AUGX, Financial), sold 109,961 shares of the company. The transaction was filed with the SEC and can be viewed through the SEC Filing.
Augmedix Inc is a company that specializes in providing remote medical documentation and live clinical support. The company's technology platform converts natural clinician-patient conversations into medical documentation and provides live support, including referrals, orders, and reminders, so clinicians can focus on what matters most: patient care.
Over the past year, the insider has sold a total of 239,396 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a trend observed over the past year, where Augmedix Inc has seen a total of 3 insider buys and an equal number of 3 insider sells.
On the day of the sale, shares of Augmedix Inc were trading at $4.13, giving the company a market capitalization of $205.194 million. According to the data provided, the stock is currently trading below the GuruFocus Value (GF Value) of $4.79, with a price-to-GF-Value ratio of 0.86, indicating that Augmedix Inc is modestly undervalued.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is determined by considering historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also includes a GuruFocus adjustment factor based on the company's historical returns and growth, as well as future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
